What is the global market size of Mycoplasma Testing Market?

Mycoplasma Testing Market size was valued at USD 262.2 Million in 2021 and is poised to grow from USD 298.91 Million in 2022 to USD 852.66 Million by 2030, at a CAGR of 14% during the forecast period (2023-2030).

Who are the key vendors in the Global Mycoplasma Testing Market?

The nature of the global mycoplasma testing market is highly competitive owing to the presence of several established players and new entrants. The market players are focusing on developing advanced technologies and solutions, expanding their product portfolios, and establishing strategic partnerships and collaborations to strengthen their position in the market. The Mycoplasma testing market is expected to continue to grow and evolve, driven by technological advancements, increasing demand for biopharmaceuticals and cell-based therapies, and stringent regulatory requirements. The market players are likely to continue to invest in R&D and innovation to develop more efficient, accurate, and cost-effective testing solutions to meet the growing demand from customers. 'Merck KGaA (Germany)', 'Thermo Fisher Scientific Inc. (US)', 'Lonza Group Ltd. (Switzerland)', 'Sartorius AG (Germany)', 'PromoCell GmbH (Germany)', 'American Type Culture Collection (ATCC) (US)', 'Agilent Technologies, Inc. (US)', 'Bionique Testing Laboratories, Inc. (US)', 'Biological Industries Israel Beit Haemek Ltd. (Israel)', 'Charles River Laboratories International, Inc. (US)', 'Creative Bioarray (US)', 'InvivoGen (US)', 'Minerva Biolabs GmbH (Germany)', 'Biological Industries US, Inc. (US)', 'Norgen Biotek Corp. (Canada)', 'Novacyt Group (UK)', 'Mycoplasma Experience (France)', 'Genscript Biotech Corporation (China)', 'GeneCopoeia, Inc. (US)', 'Jena Bioscience GmbH (Germany)'

What is the key driver of Global Mycoplasma Testing Market?

The growing demand for biopharmaceuticals and cell-based therapies is driving the Mycoplasma testing market. These products and therapies require high-quality cells that are free from Mycoplasma contamination to ensure their safety and efficacy.

What is the key market trend for Global Mycoplasma Testing Market?

Development of advanced testing technologies and platforms: The Mycoplasma testing market is witnessing the development of advanced technologies and platforms, such as PCR-based assays, nucleic acid sequencing, and flow cytometry, that offer higher sensitivity, specificity, and speed compared to traditional culture-based methods.

Which region accounted for the largest share in Global Mycoplasma Testing Market?

In 2022, North America dominated the market and accounted for a revenue share of 40.0%. Due to the well-established healthcare sector in this business and the increased prevalence of respiratory illnesses, market share growth is predicted. The existence of multinational pharmaceutical and biotech corporations in the area, as well as increased investment in R&D operations, are other factors contributing to the growth of this region.

Mycoplasma Testing Market Size, Share, Growth Analysis, By Product & Service(Assays, Kits, & Reagents (NAT Assays, Kits), By Technique(Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay, Staining, Other Techniques), By Application(Cell Line Testing, Virus Testing, End-Of-Production Cell Testing), By End User(Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, Cell Banks & Laboratories), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35I2219 | Region: Global | Published Date: September, 2024
Pages: 219 | Tables: 66 | Figures: 75

Mycoplasma Testing Market News

Agathos Biologics, in April 2023, announced that it will provide analytical testing services for life science research professionals. The only tests Agathos uses are the QIAgen-developed tests and the QIAcuity instrument. Additionally, Agathos and QIAGEN have partnered up to validation tests and validate for recombinant adeno-associated viral vector and mycoplasma tests.
Thermo Fisher Scientific, Inc. launched TrueMark STI Select Panel in February 2023. It identifies four of the most commonly contagious sexually transmitted diseases on a single panel through the polymerase chain reaction. The two organisms it detects are Mycoplasma genitalium and Chlamydia trachomatis.
Merck KGaA invested more than USD 427.3 million (EUR 399 million) in its life science R&D facilities in December 2022. The financing will supply businesses with further resources to develop the latest testing technologies, including mycoplasma.

Mycoplasma Testing Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Mycoplasma Testing Market size was valued at USD 829.6 million in 2022 and is poised to grow from  USD 9110.23 million in 2023 to USD 1911.78 million by 2031, growing at a CAGR of 9.72% during the forecast period (2024-2031).

Established and emerging companies compete with each other in the mycoplasma testing industry, introducing competition. Companies often depend on strategic alliances and innovative testing methods to firmly position themselves within the market. Regional companies are also becoming more aggressive as they expand their ranges to suit local customers. 'Merck KGaA ', 'Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd.) ', 'Charles River Laboratories International, Inc. ', 'Lonza Group Ltd. ', 'Thermo Fisher Scientific, Inc. ', 'Eurofins Scientific Group ', 'Sartorius Stedim Biotech S.A. ', 'Agilent Technologies, Inc. ', 'Meridian Bioscience, Inc. ', 'American Type Culture Collection ', 'Bionique Testing Laboratories, Inc. ', 'InvivoGen ', 'PromoCell GmbH ', 'Biological Industries Israel Beit Haemek Ltd. ', 'Clongen Laboratories, LLC ', 'Creative Bioarray ', 'Nelson Laboratories Fairfield, Inc. (A Part of Sotera Health) ', 'Norgen Biotek Corporation ', 'Biotools B & M Labs, S.A. ', 'GenBio (A Part of ExonHit Therapeutics SA) ', 'GeneCopoeia, Inc. ', 'Minerva Biolabs GmbH ', 'Mycoplasma Experience ', 'Savyon Diagnostics ', 'ScienceCell Research Laboratories'

Demand for mycoplasma testing is increasing, driven by an upsurge in the research and development of biological products in biotechnology and pharmaceuticals, including cell-based medicines and vaccines. As more and more researchers increasingly rely on cell lines for manufacturing, the requirement for a mycoplasma infection-free cell line stream has become necessary. As businesses grow through giving increased priority to quality assurance during their research operations, market demand is rising along with the need for rigorous testing methodologies.

Integration of Automation in Testing: Automation in the operations of laboratories and testing operations such as mycoplasma testing is now quite a routine affair. Automated systems ensure reduction of testing time to a level that is significantly lower, productivity increases sharply, and human errors are considerably minimized. The expanding interest of biopharmaceutical companies in enhancing process efficiency with uniform quality will keep on boosting their demand for mycoplasma testing technology companies.

According to the mycoplasma testing market forecast, North America led the market in 2023 with a revenue share of 39.04%. A combination of several factors leads to a high market share. Prevalence of respiratory disorders is also at a high level and the rising investment in biotechnology by major companies since its wide application in cancer research and developing novel biologics, vaccines, and drugs. Besides, through the development and integration of strict regulatory requirements, companies such as the FDA and the U.S. Department of Health and Human Services, in collaboration with the Centers for Disease Control and Prevention and the National Institutes of Health, continually advance standards on the testing of biological and microbiological safety of biomedical laboratories.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Mycoplasma Testing Market News

Mycoplasma Testing Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Mycoplasma Testing Market?

Who are the key vendors in the Mycoplasma Testing Market?

What is the key driver of Mycoplasma Testing Market?

What is the key market trend for Mycoplasma Testing Market?

Which region accounted for the largest share in Mycoplasma Testing Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300